NCT01054976View on ClinicalTrials.gov

The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

February 28, 2009

Study Completion Date

February 28, 2009

Conditions

Alzheimer's Disease

Interventions

DRUG

Galantamine

Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.

All Listed Sponsors

lead

Janssen Korea, Ltd., Korea

INDUSTRY

NCT01054976 - The Efficacy of Galantamine Treatment on Attention in Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter